Sangamo Therapeutics, Inc.

DB:GBY Stock Report

Market Cap: €97.3m

Sangamo Therapeutics Management

Management criteria checks 2/4

Sangamo Therapeutics' CEO is Sandy Macrae, appointed in Jun 2016, has a tenure of 7.83 years. total yearly compensation is $2.39M, comprised of 29.9% salary and 70.1% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth €164.22K. The average tenure of the management team and the board of directors is 1.8 years and 4.4 years respectively.

Key information

Sandy Macrae

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage29.9%
CEO tenure7.8yrs
CEO ownership0.2%
Management average tenure1.8yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sandy Macrae's remuneration changed compared to Sangamo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$716k

-US$258m

Sep 30 2023n/an/a

-US$250m

Jun 30 2023n/an/a

-US$199m

Mar 31 2023n/an/a

-US$127m

Dec 31 2022US$5mUS$709k

-US$192m

Sep 30 2022n/an/a

-US$178m

Jun 30 2022n/an/a

-US$172m

Mar 31 2022n/an/a

-US$176m

Dec 31 2021US$5mUS$689k

-US$178m

Sep 30 2021n/an/a

-US$181m

Jun 30 2021n/an/a

-US$135m

Mar 31 2021n/an/a

-US$124m

Dec 31 2020US$4mUS$682k

-US$121m

Sep 30 2020n/an/a

-US$76m

Jun 30 2020n/an/a

-US$102m

Mar 31 2020n/an/a

-US$96m

Dec 31 2019US$4mUS$662k

-US$95m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$104m

Mar 31 2019n/an/a

-US$90m

Dec 31 2018US$4mUS$636k

-US$68m

Sep 30 2018n/an/a

-US$63m

Jun 30 2018n/an/a

-US$62m

Mar 31 2018n/an/a

-US$58m

Dec 31 2017US$2mUS$612k

-US$55m

Compensation vs Market: Sandy's total compensation ($USD2.39M) is above average for companies of similar size in the German market ($USD406.04K).

Compensation vs Earnings: Sandy's compensation has been consistent with company performance over the past year.

CEO

Sandy Macrae (60 yo)

7.8yrs

Tenure

US$2,392,272

Compensation

Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...

Leadership Team

NamePositionTenureCompensationOwnership
Alexander Macrae
CEO, President & Director7.8yrsUS$2.39m0.17%
$ 164.2k
Prathyusha Duraibabu
Senior VP4.8yrsUS$1.06m0.026%
$ 24.8k
Nathalie Dubois-Stringfellow
Senior VP & Chief Development Officer5.3yrsUS$1.03m0.029%
$ 28.3k
Amy Pooler
Head of Researchless than a yearno data0.013%
$ 12.5k
Gregory Davis
Head of Technologyless than a yearno datano data
Aron Feingold
Head of Corporate Communications & Investor Relations Officerno datano datano data
Scott Willoughby
Senior VP2.7yrsno data0.036%
$ 34.7k
Phillip Ramsey
Head of Technical Operationsless than a yearno datano data
Stephanie J. Seiler
Head of Business Development & Alliance Managementless than a yearno datano data
David Ojala
Scientist II - Discovery & Translational Researchno datano datano data
Louise Wilkie
Vice President of Investor Relations & Corporate Communicationsno datano datano data

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: GBY's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Alexander Macrae
CEO, President & Director7.8yrsUS$2.39m0.17%
$ 164.2k
H. Parker
Independent Chairwoman of the Board9.8yrsUS$99.28k0.023%
$ 22.8k
Robert Carey
Independent Director7.8yrsUS$80.53k0.017%
$ 16.7k
Stuart Schreiber
Member of Scientific Advisory Board4.4yrsno datano data
Robert Desnick
Member of Scientific Advisory Board4.4yrsno datano data
Roger Kornberg
Member of Scientific Advisory Board4.4yrsno datano data
Samuel A. J. Aparicio
Member of Scientific Advisory Board4.4yrsno datano data
Jef Boeke
Member of Scientific Advisory Board4.4yrsno datano data
Karen Smith
Independent Director5.8yrsUS$76.78k0.018%
$ 17.9k
Megan Levings
Member of Scientific Advisory Board4.4yrsno datano data
Michael Grunstein
Member of Scientific Advisory Board4.4yrsno datano data
Douglas Higgs
Member of Scientific Advisory Board4.4yrsno datano data

4.4yrs

Average Tenure

65.5yo

Average Age

Experienced Board: GBY's board of directors are considered experienced (4.4 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.